Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia

Thrombosis and Haemostasis

Volumn 79, Issue 3, 1998, Pages 500-508

  Estellés, Amparo ^a   Gilabert, Juan ^a   Grancha, Salvador ^a   Yamamoto, Koji ^b   Thinnes, Terri ^b   España, Francisco ^a   Aznar, Justo ^a   Loskutoff, David J ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; INTERLEUKIN 1; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOAGULANT; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; VITRONECTIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; PLACENTA; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNCYTIOTROPHOBLAST; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 0031952154     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614933     Document Type: Article

References (58)

1. De Wolf F, Robertson WB, Brosens I. The ultrastructure of acute atherosis in hypertensive pregnancy. Am J Obstet Gynecol 1975; 123: 164-74.
2. Canavagh D, Kmuppel LA. Preeclampsia and eclampsia. In: Principles and Practice of Obstetrics and Perinatology. Iffy L, Kaminetzky H, eds. John Wiley & Sons, New York, NY 1981; pp 1271-89.
3. Hathaway W, Bonnar J. Hemostatic alterations in hypertensive and placental insufficiency disorders of pregnancy. In: Hemostatic Disorders of the Pregnant Woman and Newborn Infant. Hathaway W, Bonnar J, eds. John Wiley & Sons, New York, NY 1987; pp 185-201.
4. Pijnenborg R, Anthony J, Davey JA, Rees A, Tiltman A, Vercruysse L, Van Assche A. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynecol 1991; 88; 695-705.
5. Benirschke K, Kaufmann P. Hypertensive disorders. In: Pathology of the human placenta. Benirschke K, Kaufmann P, eds. Springer-Verlag, New York, NY 1990; pp 499-529.
6. Brown MA. The physiology of preeclampsia. Clin Exp Pharmacol P 1995; 22: 781-91.
7. Kruithof EKO, Tran-Thang C, Gudinchet A, Havert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitors. Blood 1987; 69: 460-6.
8. Estellés A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989; 74: 1332-8.
9. Estellés A, Gilabert J, Keeton M, Eguchi Y, Aznar J, Grancha S, Espańa F, Loskutoff DJ, Schleef RR. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 1994; 84: 143-50.
10. Camerer E, Kolsto A-B, Prydz H. Cell biology of tissue factor. The principal initiator of blood coagulation. Thromb Res 1996; 81: 1-41.
11. Spicer EK, Horton R, Bloem L, Bach R, Williams KR, Guha A, Kraus J, Lin T-C, Nemerson Y, Konigsberg WH. Isolation and cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci USA 1987; 84: 5148-52.
12. Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis 1991; 5: 197-206.
13. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
14. Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene. Expression in cultured bovine aortic endothelial cells, induction by transforming growth factor-β, lipopolysaccharide, and tumor necrosis factor-α. J Biol Chem 1989; 264: 10396-401.
15. Sawdey M, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-aα, and transforming growth factor-β. J Clin Invest 1991; 88: 1346-53.
16. Declerck PJ, De Mol M, Alessi M-C; Baudner S, Paques E-P, Preissner KT, Müller-Barghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem 1988; 263: 15454-61.
17. Mimuro J, Loskutoff DJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem 1989; 264: 936-9.
18. Deng G, Royle G, Seiffert D, Loskutoff DJ. The PAI-1/vitronectin interaction: two cats in a bag? Thromb Haemost 1995; 74: 66-70.
19. Radtke KP, Wenz K-H, Heimburger N. Isolation of plasminogen activator inhibitor-2 (PAI-2) from human placenta. Evidence for vitronectin/PAI-2 complexes in human placenta extract. Biol Chem Hoppe-Seyler 1990; 371: 1119-27.
20. Watanabe T, Araki M, Mimuro J, Tamada T, Sakata Y. Fibrinolytic components in fetal membranes and amniotic fluid. Am J Obstet Gynecol 1993: 168: 1283-9.
21. Robbie LA, Booth NA, Brown PAJ, Bennett B: Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996; 16: 539-45.
22. van Aken BE, Seiffert D, Thinnes T, Loskutoff DJ. Localization of vitronectin in the normal and atherosclerotic human vessel wall. Histochem Cell Biol 1997; 107: 313-20.
23. Estellés A, Gilabert J, España F, Aznar J, Galbis M. Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia. Am J Obstet Gynecol 1991; 165: 138-42.
24. Ballegeer V, Spitz B, Kieckens L, Moreau H, Van Assche A, Collen D. Predictive value of increased plasma levels fibronectine in gestational hypertension. Am J Obstet Gynecol 1991; 161: 432-6.
25. Caron C, Goudemand J, Marey A, Beagne D, Ducroux G, Drouvin F. Are the hemostatic and fibrinolytic parameters predictors of preeclampsia in pregnancy-associated hypertension? Thromb Haemost 1991; 66: 410-4.
26. Reith A, Booth NA, Moore NR, Cruickshank DJ, Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, preeclampsia and hydatidiform mole. Br J Obstet Gynecol 1993; 100: 370-4.
27. Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and preeclampsia. Br J Obstet Gynecol 1994; 101: 488-92
28. Friedman SA, Schiff E, Emeis JJ, Dekker GA, Sibai BM. Biochemical corroboration of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol 1995; 172: 202-3.
29. Jaattela M, Kuusela P, Sakkela E. Demonstration of tumor necrosis factor in human amniotic fluids and supernatants of placental and decidual tissues. Lab Invest 1988; 58: 48-52.
30. Eades DK, Cornelius P, Pekala PH. Characterization of the tumor necrosis factor receptor in human placenta. Placenta 1988; 9: 247-51.
31. Chen H-L, Yang Y, Hu X-L, Yelavarthi KK, Fishback JL, Hunt JS. Tumor necrosis factor α mRNA and protein are present in human placental and uterine cells at early and late stages of gestation. Am J Pathol 1991; 139: 327-35.
32. β expression in endometrium, placenta, and placental membranes. Am J Obstet Gynecol 1990; 163: 1430-7.
33. Wolf HK, Zarnegar R, Oliver L, Michalopoulos GK. Hepatocyte growth factor in human placenta and trophoblastic disease. Am J Pathol 1991; 138: 1035-43.
34. Cunninghan FG, MacDonald PC, Gant NF. In: Williams' Obstetrics, Eighteenth Edition. Appleton & Lange. Connecticut/San Mateo, CA, Norwalk, 1987.
35. Keeton M, Eguchi Y, Sawdey M, Loskutoff DJ. Cellular localization of type-1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol 1991; 142: 59-70
36. Schleef RR, Podor TJ, Dunne E, Mimuro J, Loskutoff DJ. The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator. J Cell Biol 1990; 110: 155-63.
37. Seiffert D, Ciambrone G, Wagner NV, Binder BR, Loskutoff DJ. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem 1994; 269: 2659-66.
38. Garvey W, Fathi A, Bigelow F, Carpenter B, Jimenez C. A combined elastic, fibrin and collagen stain. Stain Technology 1987; 62: 365-7.
39. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
40. Jenne D, Stanley KK. Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO J 1985; 4: 3153-7.
41. Wilcox JN, Smith KM, Schmartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
42. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: Induction of tumor necrosis factor-α and lipopolysaccharide. J Clin Invest 1996; 97: 37-46.
43. Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996; 97: 2440-51.
44. Tokunaga K, Taniguchi K, Yoda K, Shimizu M, Sakiyama S. Nucleotide sequence of a full-length cDNA for mouse cytoskeletal β actin mRNA. Nucleic Acids Res 1997; 14: 2829.
45. Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci USA 1989; 86: 9717-21.
46. Feinberg RF, Kao L-C, Haimowitz JE, Queenan Jr JT, Wun T-C, Strauss III JF, Kliman HJ. Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker of invading trophoblasts. Lab Invest 1989; 61: 20-6.
47. Estellés A, Gilabert J, Aznar J, España F, Schleef R, Loskutoff DJ. Cellular expression and potential roles of plasminogen activator inhibitors in normal and pathological pregnancies. In: Fibrinolytic inhibitors. Cellular, biological and clinical aspects. Aznar J, Gilabert J, Estellés A, eds. Garsi-Masson, Spain, 1994; pp 43-59.
48. Gilabert J, Estellés A, Aznar J, España F, Andrés C, Santos T, Vallés J. Contribution of platelets to increased plasminogen activator inhibitor type 1 in severe preeclampsia. Thromb Haemost 1990; 63: 361-6.
49. He S, Bream K, Blombäck M. Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors types 1 and 2 in severe preeclampsia. Blood Coagul Fibrin 1995; 6: 703-8.
50. Graeff H, Von Hugo R, Schrock R. Recent aspects of hemostasis, hematology and hemorrheology in preeclampsia-eclampsia. Eur J Obstet Gynec Reprod Biol 1984; 17: 91-102.
51. Estellés A, Gilabert J, España F, Aznar J, Gómez-Lechón MJ. Fibrinolysis in preeclampsia. Fibrinolysis 1987; 1: 209-13.
52. Fox H. Placental pathology: a contemporary approach. In: Obstetrics and Gynecology Annual. Vol 14. Wynn RM, ed. Appleton-Century-Crofts, Connecticut 1985; pp 427-40.
53. Chen G, Wilson R, Wang SH, Zheng HZ, Walker JJ, Mckillop JH. Tumour necrosis factor-alpha (TNF-alpha) gene polymorphism and expression in pre-eclampsia. Clin Exp Immunol 1996; 104: 154-9.
54. Kanfer A, Bruch JF, Nguyen G, He CJ, Delarue F, Flahaut A, Nessmann C, Uzan S. Increased placental antifibrinolytic potential and fibrin deposits in pregnancy-induced hypertension and preeclampsia. Lab Invest 1996, 74: 253-8.
55. Lucore CL, Fujii S, Wun T-C, Burton BE, Billadello JJ. Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor. J Biol Chem 1988; 263: 15845-8.
56. Sawdey M, Loskutoff DJ. Regulation of type one plasminogen activator inhibitor gene expression in cultured endothelial cells and the vessel wall. In: Arteriosclerosis: Cellular and Molecular Interactions in the Artery Wall. Fedoroff S, ed. Plenum Publishing Corp., New York, NY 1991; pp 187-208.
57. Schneiderman J, Bordin GM, Engelberg I, Adar R, Seiffert D, Thinnes T, Bernstein EF, Dilley RB, Loskutoff DJ. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. J Clin Invest 1995; 96: 639-45.
58. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-9.